United States Validation of the Cambridge Pulmonary Hypertension Outcome Review (CAMPHOR)

Gomberg‐Maitland, Mardi; Thenappan, Thenappan; Rizvi, Kamran; Chandra, Sonal; Meads, David; McKenna, Stephen P.

doi:10.1016/j.healun.2007.10.004

Cited by 75 publications

(68 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…It focuses on the impact that functional ability and symptoms have on QoL, in a "needs-based" model, exploring the extent to which PH patients are able to meet their needs. It is, thus, a valuable instrument and has also been recently validated in the United States [20]. QoL in our Eisenmenger cohort improved significantly after 3 months of treatment with sildenafil.…”

Section: Discussionmentioning

confidence: 75%

Quality of life and functional capacity can be improved in patients with Eisenmenger syndrome with oral sildenafil therapy

Tay¹,

Papaphylactou²,

Diller³

et al. 2011

International Journal of Cardiology

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 75%

Quality of life and functional capacity can be improved in patients with Eisenmenger syndrome with oral sildenafil therapy

Tay¹,

Papaphylactou²,

Diller³

et al. 2011

International Journal of Cardiology

View full text Add to dashboard Cite

“…The reliability and validity of the CAMPHOR in a United States population was recently tested by Gomberg-Maitland and colleagues (30) In that study, face and content validity were re-assessed among a subset of patients; no significant modifications to the original instrument were made. Overall, the U.S. CAMPHOR demonstrated good construct validity with respect to the SF-36 and 6MWD.…”

Section: Studies Of Hrqol In Pahmentioning

confidence: 99%

Health-related Quality of Life and Patient-reported Outcomes in Pulmonary Arterial Hypertension

Chen¹,

Taichman²,

Doyle³

2008

Proceedings of the American Thoracic Society

101

View full text Add to dashboard Cite

Advances in our understanding of the basic pathophysiology of pulmonary arterial hypertension (PAH) has led to an expanding number of therapeutic options. The ultimate goals of therapy are to lengthen survival while improving symptoms and quality of life. A wealth of research in other conditions has established health-related quality of life (HRQoL) to be an important clinical endpoint. Until recently, however, little was known about HRQoL in PAH, and how best to measure it. Over the past few years, several studies have begun contributing to this growing area of research. Instruments used to assess HRQoL have varied between studies. The extent to which these instruments are valid in PAH depend on their specific measurement properties. In this article, we provide an overview of the different types of patient-reported outcomes (PROs) used in PAH, focusing in particular on the measurement of HRQoL. In the process, we review the current literature on HRQoL in PAH, summarize the available data from randomized controlled trials, and discuss the implications of these findings on future research. Despite significant progress, the study of HRQoL in PAH remains a nascent field relative to other conditions. As the use of PROs continues to increase, additional work will be needed to begin standardizing the reporting and interpretation of such outcomes in future clinical trials.

show abstract

“…In 2008, the US CAMPHOR (Cambridge Pulmonary Hypertension Outcome Review) was developed to assess impairment, disability, and needs-based healthrelated quality of life in adults with PAH. 25 Use of the CAMPHOR may reveal different findings than the MOS SF-36 and the SGRQ. The SGRQ was developed to assess impact of symptoms on activity with respiratory disease such as chronic obstructive pulmonary disease.…”

Section: Physical Functioningmentioning

confidence: 99%

Human Responses to Pulmonary Arterial Hypertension

Matura

Carroll

2010

Journal of Cardiovascular Nursing

View full text Add to dashboard Cite

Pulmonary arterial hypertension (PAH) is a devastating disease characterized by elevation in pulmonary artery pressures causing progressive symptoms that lead to functional decline and poor quality of life. There are multiple causes of PAH including familial disease, connective tissue disease, and HIV. The estimated life expectancy is 4 years after onset of symptoms and approximately 6 to 7 years with PAH treatment. Much of the current research has focused on pharmacological treatments to improve functional status and decrease mortality. A comprehensive literature review was conducted using the CINAHL, PubMed, and MEDLINE to identify and synthesize current studies on human responses to PAH organized by emotional responses and physical functioning. Eight studies fulfilled the search criteria. Patients with PAH were learning to cope and live with uncertainty and treatment. Pulmonary arterial hypertension produced the emotional responses of anxiety, depression, and panic attacks along with impairments in cognition and memory as well as reductions in physical functioning.

show abstract

United States Validation of the Cambridge Pulmonary Hypertension Outcome Review (CAMPHOR)

Cited by 75 publications

References 25 publications

Quality of life and functional capacity can be improved in patients with Eisenmenger syndrome with oral sildenafil therapy

Quality of life and functional capacity can be improved in patients with Eisenmenger syndrome with oral sildenafil therapy

Health-related Quality of Life and Patient-reported Outcomes in Pulmonary Arterial Hypertension

Human Responses to Pulmonary Arterial Hypertension

Contact Info

Product

Resources

About